Global Hypophosphatasia Treatment Market, By Type (Odontohypophosphatasia, Pseudohypophosphatasia and Others), Therapy Type (Enzyme Replacement Therapy, Occupational Therapy and Others), Treatment (Medication, Surgery), Drugs (Asfotase Alfa, Non-Steroidal Anti-Inflammatory Drugs, Thiazide Diuretics and Others), Route of Administration (Oral, Injectable), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Hypophosphatasia Treatment Market Analysis and Size
As per the National organization for Rare Disorders, the overall occurrence of hypophosphatasia is unknown, but in Canada, the extreme form of hypophosphatasia affects about 1 in 100,000 live births. Hypophosphatasia symptoms can largely vary from one person to another, sometimes even among the members of the same family. The sign and symptoms includes hypercalcemia, soft bones, short stature and weak bones with loss of mobility, and may also lead to premature death.
Data Bridge Market Research analyses a growth rate in hypophosphatasia treatment market in the forecast period 2023-2030. The expected CAGR of hypophosphatasia treatment market is tend to be around 4.3% in the mentioned forecast period. The market value is USD 2.7 billion in 2022, and it would grow upto USD 3.78 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Hypophosphatasia Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023-2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Odontohypophosphatasia, Pseudohypophosphatasia and Others), Therapy Type (Enzyme Replacement Therapy, Occupational Therapy and Others), Treatment (Medication, Surgery), Drugs (Asfotase Alfa, Non-Steroidal Anti-Inflammatory Drugs, Thiazide Diuretics and Others), Route of Administration (Oral, Injectable), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Kirin Holdings Company, Limited (Japan), Vericel Corporation (U.S.), Mereo Biopharma Group PLC (U.K.), Novartis AG (Switzerland), AM-Pharma B.V (Netherlands), Alexion Pharmaceuticals, Inc. (U.S.), Bayer AG (Germany), and Pfizer, Inc (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Hypophosphatasia also known as rathburn disease which is a rare type of disease that is caused due to an inborn error of metabolic genetic disorder mainly characterized by the abnormal development of bones and teeth. This is also caused due to defective mineralization or calcification. The symptoms associated with this disease can vary greatly from one person to another. HPP can be inherited in an autosomal recessive or autosomal dominant manner depending on the specific form.
Hypophosphatasia Treatment Market Dynamics
Drivers
- Increased Clinical Trials
In recent times, clinical trials are conducted, wherein a huge number of organizations are actively participating in numerous research programs to develop novel therapies for infantile and juvenile-onset hypophosphatasia treatment. The increased introduction of numerous novel therapy, orphan drug designation for rare diseases, breakthrough therapy designation, financial incentives and increased grants by the government are contributing in pushing the market growth. Furthermore, clinical studies on product efficacy and safety are projected to increase the hypophosphatasia treatment during the forecast period.
- Growing Incidences Of Hypophosphatasia
The accurate prevalence rate of HPP is unknown and it ranges by form and region. In the U.S., it affects about 500-600 individuals every year. Furthermore, in some inbred populations, such as Canadian Mennonites, the frequency is as high as 1 case per 2500 newborns. According to the records of NCBI, the occurrence of severe forms has been assessed to 1/300,000 in Europe and 1/100,000 in North America. This boost the market growth.
Opportunities
- Growing Demand of Diverse Treatment Methods
There are numerous treatment methods that are helping in boosting the growth of the market. There are treatments such as ventilator support, occupational therapy and surgery that are helpful for bone fractures. For instance, the enzyme replacement therapy was recently approved in October 2015 to treat abnormal bone structure in people suffering from onset hypophosphatasia (HPP). The HPP community are helping to bring many new programs that will bring varied treatment options to people suffering from rare diseases.
Restraints/Challenges
- Discontinuation of Drug Trials
The drug development associated with the disease has faced many obstacles such as many therapies have failed to reveal efficacy or were related with major toxicity. Thus, this hampers the growth of the market.
This hypophosphatasia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hypophosphatasia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Hypophosphatasia Treatment Market Scope
The hypophosphatasia treatment market is segmented on the basis of treatment, type, therapy type, drugs, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Types
- Odontohypophosphatasia
- Pseudohypophosphatasia
- Others
Therapy Type
- Enzyme Replacement Therapy
- Occupational Therapy
- Others
Treatment
- Medication
- Surgery
Drugs
- Asfotase Alfa
- Non-Steroidal Anti-Inflammatory Drugs
- Thiazide Diuretics
- Others
Route of Administration
- Oral
- Injectable
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Hypophosphatasia Treatment Market Regional Analysis/Insights
The hypophosphatasia treatment market is analyzed and market size insights and trends are provided by treatment, type, therapy type, drugs, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the hypophosphatasia treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific will expect positive growth for hypophosphatasia treatment market throughout the forecasted period because of the adoption of new products and surge in demand for hypophosphatasia treatment in developing countries such as India and China.
North America dominates the market due to the increasing research & development of disease from the established major market players. It is also due to increase in product offerings, more affordability, and increase in demand for early treatment.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Hypophosphatasia Treatment Market Share Analysis
The hypophosphatasia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hypophosphatasia treatment market.
Key players operating in the hypophosphatasia treatment market include:
- Kirin Holdings Company, Limited (Japan)
- Vericel Corporation (U.S.)
- Mereo Biopharma Group PLC (U.K.)
- Novartis AG (Switzerland)
- AM-Pharma B.V (Netherlands)
- Alexion Pharmaceuticals, Inc. (U.S.)
- Bayer AG (Germany)
- Pfizer, Inc (U.S.)
SKU-